Triumph Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Triumph Capital Management's BMY Position: Q3 2026 in Review
Triumph Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 8.9% in Q3 2026, selling an estimated $117K and leaving 18,829 shares worth $1.17M. The position accounts for 0.2% of the portfolio, ranked #118.
Triumph Capital Management first reported a position in BMY in Q2 2023 and has held it in 14 quarters since. The position peaked at $1.6M in Q1 2025. 2,570 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Triumph Capital Management held 18,829 shares of Bristol-Myers Squibb worth $1.17M as of Q3 2026.
- Triumph Capital Management sold 1,849 Bristol-Myers Squibb shares in Q3 2026, an estimated $117K.
- Bristol-Myers Squibb made up 0.2% of Triumph Capital Management's portfolio in Q3 2026, its #118 holding.
- Triumph Capital Management first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 14 quarters since.
- Triumph Capital Management's Bristol-Myers Squibb position peaked at $1.6M in Q1 2025.
- 2,570 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.